SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.
HONG KONG, Jun 15, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based […]